- Nuvation Bio Inc. (NUVB, Financial) will announce its first-quarter 2025 financial results on May 7, 2025.
- Taletrectinib's New Drug Application has a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025.
- The company's webcast will begin at 4:30 p.m. ET on the earnings announcement date.
Nuvation Bio Inc. (NUVB), a prominent global oncology company, is scheduled to announce its first-quarter 2025 financial results on May 7, 2025. The results will be detailed in a conference call that will commence at 4:30 p.m. ET, where company executives will also provide updates on their ongoing programs, drug pipelines, and commercial strategies, particularly focusing on taletrectinib.
The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025, for the New Drug Application of taletrectinib, a third-generation ROS1 inhibitor being developed by Nuvation Bio. This drug is part of Nuvation Bio's diverse pipeline, which also includes safusidenib, NUV-1511, and NUV-868, aimed at revolutionizing cancer treatment.
Investors and interested parties can access a live webcast of the earnings call through Nuvation Bio's investor relations website. The webcast will provide an in-depth view of the company's financial performance and strategic initiatives. A replay will also be available after the call concludes, providing further insights into the company's ongoing projects and future prospects.
